title: Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis.
abstract: OBJECTIVE
  To compare peritonitis occurrence and outcome in a large U.K. study Multicentre Investigation of Icodextrin in Ambulatory Dialysis (MIDAS).
  
  
  METHODS
  Prospective, randomized, controlled 6-month comparison of icodextrin with glucose for the long dwell in continuous ambulatory peritoneal dialysis (CAPD) patients.
  
  
  METHODS
  Eleven CAPD units in U.K. teaching hospital.
  
  
  METHODS
  A total of 209 patients established on CAPD for at least 3 months (103 control, 106 icodextrin). Twenty-three control (C) and 22 icodextrin (I) patients experienced peritonitis during the study.
  
  
  METHODS
  Patients who had peritonitis remained on treatment (unless CAPD was withdrawn, temporarily or permanently).
  
  
  METHODS
  The main outcome measures were the rate of peritonitis and duration of CAPD treatment prestudy; the rate of peritonitis episodes and their outcome during study; the effect of peritonitis on laboratory variables, serum icodextrin metabolites, and ultrafiltration efficacy.
  
  
  RESULTS
  Prestudy: Nine (39%) of C but 14 (64%) of I patients had suffered previous peritonitis episode(s), with overall rates of 0.58 and 0.78 episodes per patient-year, respectively. DURING STUDY: There were 31 C episodes and 35 I episodes, with overall rates of 0.76 and 0.93 per patient-year, respectively. The increase in the C and I groups was 31% and 19%, respectively. Serum osmolality and sodium levels were unaffected by peritonitis, and there was no increase in serum icodextrin metabolites during peritonitis. Overnight ultrafiltration volume during peritonitis (mean +/- SD) declined slightly from 218 +/- 354 mL to 185 +/- 299 mL (NS) in the control group, but increased in the icodextrin group from 570 +/- 146 mL to 723 +/- 218 mL (p < 0.01).
  
  
  CONCLUSIONS
  Using icodextrin for the long dwell in CAPD does not increase the rate of peritonitis, nor does it alter the outcome of peritonitis. Peritonitis does not affect uptake of icodextrin from the peritoneum.
authors.affiliation: Manchester Royal Infirmary, U.K.
authors.forename: R
authors.initials: R
authors.lastname: Gokal
authors.forename: C D
authors.initials: CD
authors.lastname: Mistry
authors.forename: E M
authors.initials: EM
authors.lastname: Peers
mesh_terms: D002712:Chlorides / Q000097:blood; D015314:Dialysis Solutions / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005936:Glucans / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005947:Glucose / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006440:Hemofiltration; D006801:Humans; D007958:Leukocyte Count; D009994:Osmolar Concentration; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D010537:Peritoneum / Q000378:metabolism; D010538:Peritonitis / Q000097:blood / Q000209:etiology*; D011188:Potassium / Q000097:blood; D011446:Prospective Studies; D012964:Sodium / Q000097:blood; D016896:Treatment Outcome
chemical_list: D002712:Chlorides; D015314:Dialysis Solutions; D005936:Glucans; D012964:Sodium; D005947:Glucose; D011188:Potassium